Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H16BrF3N4O |
| Molecular Weight | 429.234 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C1=CN=C(C=C1)N2CC[C@H](C2)NC(=O)NC3=CC=CC=C3Br
InChI
InChIKey=JYILLRHXRVTRSH-GFCCVEGCSA-N
InChI=1S/C17H16BrF3N4O/c18-13-3-1-2-4-14(13)24-16(26)23-12-7-8-25(10-12)15-6-5-11(9-22-15)17(19,20)21/h1-6,9,12H,7-8,10H2,(H2,23,24,26)/t12-/m1/s1
| Molecular Formula | C17H16BrF3N4O |
| Molecular Weight | 429.234 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
SB-705498 is a selective vanilloid receptor-1 (VR1/TRPV1) antagonist developed by GlaxoSmithKline. The drug was tested in phase II of clinical trials for the treatment of pain (dental, rectal, in migraine) and rhinitis/cough. The development of the drug has been terminated by unknown reason (SB-705498 is no longer in GSK pipeline).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17392405 |
3.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17659837 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
196.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg 2 times / day multiple, nasal dose: 12 mg route of administration: Nasal experiment type: MULTIPLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
86.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg single, nasal dose: 12 mg route of administration: Nasal experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
42.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17659837 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3416.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg 2 times / day multiple, nasal dose: 12 mg route of administration: Nasal experiment type: MULTIPLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
903.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23909699 |
12 mg single, nasal dose: 12 mg route of administration: Nasal experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
54.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17659837 |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
SB-705498 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. | 2007-06 |
|
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. | 2006-06-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01424514
Non Allergic Rhinitis: 12mg intra-nasal SB-705498 once daily. Chronic Cough: take 400 or 600mg orally.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21951314
The pharmacological activity of SB-705498 was characterized on HEK293 cells expressing the human TRPV1, using fluorometric calcium imaging. The cells were treated with different concentrations (10(-5)-10(-10) M) of the drug for 1 min or with 1uM for 30 min. The IC50 for the inhibition of 20 nM capsaicin-induced responses was estimated as 46 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:15:52 GMT 2025
by
admin
on
Mon Mar 31 21:15:52 GMT 2025
|
| Record UNII |
T74V9O0Y2W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T74V9O0Y2W
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
SB-705498
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
DTXSID20198236
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
9910486
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
300000042476
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
501951-42-4
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
DB11883
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY | |||
|
CHEMBL207433
Created by
admin on Mon Mar 31 21:15:52 GMT 2025 , Edited by admin on Mon Mar 31 21:15:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |